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Sinonasal polyposis (SNP) is a chronic inflammatory pathology with an unclear aetiopathogenesis. Human papillomavirus (HPV)
infection is one candidate for the development of SNP for its epithelial cell trophism, hyperproliferative effect, and the induction of
immune-modulatory molecules as HLA-G. We enrolled 10 patients with SNP without concomitant allergic diseases (SNP-WoAD),
10 patients with SNP and suffering from allergic diseases (SNP-WAD), and 10 control subjects who underwent rhinoplasty. We
analyzed the presence of high- and low-risk HPV DNA and the expression of membrane HLA-G (mHLA-G) and IL-10 receptor
(IL-10R) and of soluble HLA-G (sHLA-G) and IL-10 by polyp epithelial cells. The results showed the presence of HPV-11 in 50% of
SNP-WoAD patients (OR:5.5), all characterized by a relapsing disease. HPV-11 infection was absent in nonrelapsing SNP-WoAD
patients, in SNP-WAD patients and in controls, supporting the hypothesis that HPV-11 increases risk of relapsing disease. HPV-11
positive SNP-WoAD patients presented with mHLA-G and IL-10R on epithelial cells from nasal polyps and showed secretion of
sHLA-G and IL-10 in culture supernatants. No HLA-G expression was observed in HPV negative polyps.These data highlight new
aspects of polyposis aetiopathogenesis and suggest HPV-11 and HLA-G/IL-10 presence as prognostic markers in the follow-up of
SNP-WoAD.
1. Introduction
Sinonasal polyposis (SNP) is a chronic inflammatory pathol-
ogy characterized by the formation of nasal polyps at the
level of the nasal cavity and paranasal sinuses, resulting
from an edematous multifocal degeneration of the mucosa.
These benign lesions affect approximately 1–4% of the general
population, with a slight preference towards elderly men [1].
They aremost often treated with steroids or surgery, although
nasal polyps removed by surgery have a 70% chance of recur-
rence.Themechanisms for polyps development are not clear,
even though allergies, asthma, aspirin-sensitive individuals,
and chronic sinus infections are frequently associated [2, 3].
Viral infection has been postulated to be one important
aetiological factor in the pathogenesis, progression, and
recurrence of nasal polyps [4], with human papillomavirus
(HPV) infection as a candidate for the development of nasal
polyps [5, 6].
HPV is a small unenveloped double-stranded DNA virus
with strict tissue and species specificity. Many different
papillomaviruses infect animals, and over 150 genotypes have
been so far identified in humans. Papillomaviruses infect
squamous epithelia as skin and mucosae. The mucosal types
of HPV fall in two groups: low-risk types (LR-HPV) (mainly
HPV-6 and -11), which induce benign cell hyperproliferation,
and the high-risk types (HR-HPV), which lead to malig-
nancies as invasive cervical carcinoma, anal cancer, and
oropharyngeal carcinomas.
Previous studies have shown that HPV infection may
be associated with human nasal polyposis, such as inverted
papilloma [5, 6]. However, the role of HPV infection and type
in SNP has not been clearly demonstrated. Moreover, HPV
Hindawi Publishing Corporation
Journal of Immunology Research
Volume 2014, Article ID 407430, 8 pages
http://dx.doi.org/10.1155/2014/407430
2 Journal of Immunology Research
infection is often transient and the host immune system could
counteract viral invasion leading to lesion regression [7], as
the host immune system is able to counteract the infection.
On the other hand,HPV is able to downregulate host immune
system [8], blocking interferon response, antigen processing,
and presentation [9] andmodifying human leukocyte antigen
(HLA)-G expression [10, 11].
HLA-G is a nonclassical HLA class I molecule with a
physiological tissue-restricted distribution in cytotrophoblast
[12], amniotic cells [13], thymus [14], and endothelial cells of
chorionic blood vessels [15]. HLA-Gmolecules are generated
by an alternative splicing of the primary transcript of the
gene; HLA-G exists as four-membrane bound (HLA-G1, -
G2, -G3, and -G4) and three soluble isoforms (HLA-G5, -G6,
and -G7) [16, 17]. HLA-G exhibits low allelic polymorphisms
in comparison with classical HLA class I genes, with only
50 alleles (IMGT HLA database, December 2013) and 16
proteins. HLA-G is characterized by tolerogenic functions,
inducing apoptosis of activated CD8+ T cells [18], promoting
T regulatory cells [19], modulating the activity of natural
killer cells [20] and of dendritic cells [21], and blocking
allocytotoxic T lymphocyte response [22]. These immun-
oregulatory functions are mediated by the interaction
of HLA-G molecules with specific inhibitory receptors:
ILT-2 (LILRB1/CD85j), ILT-4 (LILRB2/CD85d), CD8, and
KIR2DL4 (CD158d) expressed by immune cells [23]. We
previously demonstrated a generalized defect in sHLA-G
production by peripheral blood mononuclear cells of SNP
patients [23] that seems to be mainly related to the inter-
leukin (IL)-10/HLA-G pathway. IL-10 is one of the main
HLA-G inducers [24] but it does not seem to be able to
upmodulate sHLA-G production in SNP patients despite
the elevated/normal production of IL-10. Since previous
studies reported an involvement of HLA-G molecules in
HPV-associated tumours [10, 11, 25–27], we determined the
presence of HPV infection andHPV types in the nasal polyps
of patients affected by SNP and the possible effect on HLA-G
expression.
2. Materials and Methods
2.1. Population. A total of 20 subjects whomet the diagnostic
criteria of nasal polyps were recruited from the Operative
Unit of Otolaryngology, St. Anna Hospital, Ferrara, between
the years 2010 and 2013. Among these patients, 15 were
male and 5 were female. The median age of these patients
was 52.8 years (range: 37–84 years, SD 15.2). All of the 20
patients underwent surgery for the removal of nasal polyps
at least once, and in 11 cases such surgery was performed
twice. Ten patients presented with allergic diseases (SNP-
WAD) while 10 patients did not present with any allergic
diseases (SNP-WoAD). All the patients were followed for
almost two years from the first surgery, in order to identify the
occurring relapses. All the polyps resulted to be of edematous
type.
In addition, 10 healthy individuals surgically treated for
rhinoplasty (6 males and 4 females) with a median age of 47.5
years (range: 34–79 years, SD 10.2) were included.
Nasal polyps from patients or middle turbinate mucosa
from healthy subjects were removed and used for experi-
ments.
All subjects agreed to participate in this study by provid-
ing written informed consent (University of Ferrara Ethical
Committee Protocol N∘ 140194).
2.2. Nasal Biopsies. Nasal biopsies were collected from infe-
rior turbinates in controls or from nasal polyps in SNP
patients. The nasal biopsies were freshly processed to isolate
nasal epithelial cells as previously described [28]. Polyps
were washed in DMEM and incubated with 0.1% collage-
nase in DMEM-F12 supplemented with 100 IU/mL of peni-
cillin/streptomycin at 4∘C overnight. After incubation, the
nasal epithelial cells were isolated by gentle agitation. The
residual polyp tissue was discarded. After centrifugation at
1200 rev/min for 5min, the supernatant was removed and
1mL of pure FCS was added to the cell pellet to neutralize
the enzyme. After further centrifugation, the cells were
suspended in DMEM-F12 supplemented with antibiotics and
10%FCS.Thedissociated cells were used to separate epithelial
cells.
2.3. Epithelial Cell Purification. Epithelial cells were isolated
from polyps dissociated cells by anti-EpCAM (Ber-EP4)
coated immune-magnetic beads (Dynal CELLection Epithe-
lial Enrich, Dynal AS, Oslo, Norway).
Epithelial and residual cells were grown for 5 days in
DMEM-F12 medium added with penicillin/streptomycin,
Hepes buffer, L-glutamine, and 10% FBS.
2.4. DNA Extraction and HPV-PCR. Genomic DNA was
extracted from epithelial and residual cells usingDNA sorb-B
extraction kit (Sacace Biotechnologies, Como, Italy), accord-
ing to the manufacturer’s instructions. The presence of HR-
HPV (HPV-16, -18, -31, -33, -35, -39, -45, -52, -53, -56, -
58, -59, -66, and -70) and LR-HPV (HPV-6 and HPV-11)
was investigated by PCR using the HPV high-risk screen
amplification kit and the HPV6/11 screen amplification kit
(Sacace Biotechnologies).
2.5. Flow Cytometry. HLA-G and IL-10R expression on polyp
cells was monitored by immunofluorescence assay with anti-
HLA-G (87G-Alexa Fluor 488, Exbio, Praha, CZ) and anti-
IL-10R (anti-IL-10RPE, Chemicon, Millipore, MA, USA)
moAbs. Anti-isotype controls (Exbio, Praha, CzechRepublic)
were performed. Cells viability was assessed by propidium
iodide staining. Cells were analyzed by a flow cytofluori-
metric approach with FACSCount flow cytometer (Becton
Dickinson, San Jose, CA, USA) using standard settings and
CellQuest software (Becton Dickinson, San Jose, CA, USA)
for data analysis.
2.6. Immunofluorescence. Adherent epithelial cells and
adherent residual cells were analyzed by immunofluorescence
with anti-Mucin8-FITC or fibroblast marker-FITC (Santa
Cruz Biotechnology, TX, USA) and anti-HLA-G 87G-PE
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Figure 1: PCR products obtained from HPV-11 DNA analysis by HPV6/11 screen amplification kit (Sacace Biotechnologies) of (a) epithelial
cells and (b) residual cells from polyps of the 5 relapsing SNP-WoAD patients. Internal control at 723 bp, HPV-11 at 425 bp. The kit has a
sensitivity of 500 copies/mL.
(Exbio). All samples were observed under a UV light
microscope (Nikon Eclipse TE2000S, Nikon, Italy).
2.7. sHLA-G Enzyme-Linked Immunosorbent Assay (ELISA).
sHLA-G levels in epithelial cell culture supernatants were
assayed in triplicate as previously reported [29–31] using, as
capture antibody, the monoclonal antibody (MoAb) MEM-
G9 (Exbio), which recognizes the HLA-G molecule, in 𝛽2-
microglobulin associated form. The intra-assay coefficient of
variation (CV) was 1.4% and the interassay CVwas 4.0%.The
limit of sensitivity was 1.0 ng/mL.
2.8. IL-10 ELISA. IL-10 concentrations were determined in
triplicate using the commercial Human IL-10 BioSource
immunoassay kit (Human IL-10 US, BioSource, Camarillo,
CA, USA) with a detection limit of 0.2 pg/mL.
2.9. Statistical Analysis. Thesampleswere analyzedwith odds
ratio, logistic regression, and Student’s 𝑡-test. Significant 𝑃
values were considered <0.05.
3. Results
3.1. Presence of HPV-11 Infection in Polyp Biopsies from
Relapsing SNP-WoAD Patients. We detected the presence of
LR-HPV-11 in 50% (5/10) of samples obtained from patients
with SNP-WoAD. Interestingly, these 5 patients presented
with a relapsing SNP-WoAD. The other 5 SNP-WoAD did
not preset LR-HPV infection and were not characterized by a
relapsing disease. None of the SNP-WoAD patients presented
with HR-HPV infection. We found no LR-HPV and HR-
HPV infection neither in biopsies obtained from SNP-
WAD patients nor in healthy controls. These results sustain
a role for HPV-11 in the development of relapsing SNP-
WoAD (OR: 5.5, 95%, CI: 0.8–38.7). The logistic regression
analysis sustains the role of HPV-11 infection as a risk factor
for the development of relapsing SNP-WoAD, regardless
of gender, age, disease course, and number of relapses
(𝑃 = NS).
3.2. Presence of HPV-11 Infection in the Epithelial Fraction of
Polyps from Relapsing SNP-WoAD Patients. In order to assess
the polyp cell fraction infected by HPV-11, we processed
the HPV-11 positive biopsies and purified the epithelial cells.
The positivity for the presence of HPV-11 was maintained
only in the fraction containing epithelial cells (Figure 1(a)).
Conversely, the residual fraction was not positive for the
presence of HPV-11 DNA (Figure 1(b)).
3.3. HLA-G Expression in the Epithelial Fraction of Polyps
from Relapsing SNP-WoAD Patients. Since HPV infection
modifies HLA-G expression [10, 11, 25–27], we analyzed
the different fraction of cells extracted from nasal polyps
for HLA-G expression. Only epithelial cells (Mucin 8positive)
arising from HPV-11 positive relapsing SNP-WoAD patients
showed HLA-G membrane expression (Figure 2(a)). Con-
versely, the epithelial cells from biopsies of SNP-WoAD
patients without HPV infection, of SNP-WAD patients and
of healthy controls, presented with no HLA-G expression
(Figure 2(a)). In the residual fraction obtained after the
purification of epithelial cells, which consisted in fibroblast
cells (fibroblast markerpositive), no HLA-G expression was
found in all the three groups of subjects (Figure 2(b)).
3.4. sHLA-G and IL-0 Expression in the Epithelial Fraction
of Polyps from Relapsing SNP-WoAD Patients. Since HLA-
G molecules are present in both membrane and soluble
isoforms, we analyzed the epithelial cell culture supernatants
from SNP-WoAD for sHLA-G presence. We found the pres-
ence of sHLA-G molecules only in HPV-11 positive samples
(Figure 3(a)), while no sHLA-G was observed in HPV nega-
tive samples (Figure 3(a)) and in all the fibroblasts cultures
(data not shown). Interestingly, the secretion of sHLA-G
decreased over 5 days of culture. Since IL-10 is known to be
an inducer of HLA-G expression and we proposed an impli-
cation in SNP [32], we analyzed the levels of IL-10 in epithelial
cell culture supernatants. We documented the secretion of
IL-10 in both HPV-11 positive and HPV negative epithelial
cell cultures (Figure 3(b)). In HPV negative samples, IL-10
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Figure 2: Immunofluorescence analysis of (a) epithelial cells and (b) residual cells (fibroblasts) from representative SNP-WoAD and SNP-
WADpatients and controls.The cells were stainedwith anti-Mucin8-FITCor fibroblastmarker-FITC (SantaCruz Biotechnology) and 87G-PE
(Exbio).
decreased after 48 hrs while it lasted for 5 days of culture in
HPV-11 positive samples (Figure 3(b)).
Since IL-10 interacts with a specific receptor (IL-10R)
at the cell surface, we analyzed its expression on the cells
extracted from polyp biopsies. We observed IL-10R on the
27% (median) of epithelial cells from SNP-WoAD patients
with HPV-11 infection (Figure 4), while only the 1.4% of
epithelial cells from SNP-WoAD patients without HPV infec-
tion expressed this receptor (Figure 4) (𝑃 = 0.0022, Student’s
𝑡-test).
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Figure 3: (a) sHLA-G and (b) IL-10 levels in epithelial cell culture supernatants fromHPV negative andHPV-11 positive SNP-WoAD patients
during a 5-day in vitro culture.
4. Discussion
Previous studies in literature have analyzed the role of HPV
infection in SNP, demonstrating different correlation ranges
[5, 6, 33]. We hypothesize that these differences may be
due to the absence of a preselection of patients according
to the presence or absence of allergic diseases that could
be a confounder for the results observed. In our study, we
enrolled the patients on the basis of the characteristics of SNP.
Interestingly, the 50% of the SNP-WoAD patients showed
positivity for HPV-11 infection and a relapsing disease. On
the contrary, HPV infectionwas absent in SNP-WADpatients
and in SNP-WoAD patients without a relapsing disease.
These results confirm the importance of the methodological
approach in the selection of patients for the study of this
pathology and support previous results [33], where HPV-11
was observed as the prevalent infection SNP. Interestingly,
HPV infection was restricted to epithelial cells, as it is known
to be highly tropic for epithelial cells, while no infection sign
was evidenced in fibroblast cells.
The presence of allergic diseases could increase the risk
of SNP because of the creation of an inflammatory nasal
environment. On the contrary, in the absence of an allergic
background, the causes could be found in different envi-
ronmental factors. In particular, we observed the presence
of HPV-11 infection only in relapsing SNP patients, where
the persistence of a viral infection could worsen the disease
follow-up.
We then evaluated the immunologicalmechanismswhich
can be the basis of the virus effect on SNP-WoAD aetiopatho-
genesis. Interestingly, we found HLA-G expression in HPV-
11 positive SNP-WoAD patients, with a secretion of HLA-G
molecules that lasted for 5 days of culture.The same behavior
was followed by IL-10 thatwasmainly present in epithelial cell
6 Journal of Immunology Research
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Figure 4: IL-10R expression on epithelial cells from HPV negative and HPV-11 positive SNP-WoAD patients. Grey histogram: anti-isotype
controls (Exbio) and white histogram: IL-10R (anti-IL-10RPE) (Chemicon).
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culture supernatants of SNP-WoAD patients. The presence
of HPV-11 infection upmodulated also IL-10R on epithelial
cells, suggesting a direct role of IL-10 in controlling HLA-
G expression. On the contrary, the low IL-10R expression
in HPV negative samples could explain the absence of
HLA-G expression, even in the presence of IL-10 secretion.
Interestingly, we previously reported the absence of sHLA-G
production by peripheral blood mononuclear cells (PBMCs)
from SNP-WoADpatients after lipopolysaccharide activation
and reported IL-10 secretion after PBMCs lipopolysaccharide
activation but no induction of HLA-G expression that was
restored only after exogenous IL-10 addition [32]. These dif-
ferences inHLA-G/IL-10 expression pattern between PMBCs
and polyp epithelial cells from SNP-WoAD patients support
the involvement of HPV-11 infection in local HLA-G and IL-
10 induction. In fact, previous results documented the ability
of HPV-11 E6 in inducing IL-10 expression [34]. HPVE6 gene
is one of themost relevant viral gene products that contribute
to the immortalization and transformation of HPV-infected
cells [35].The activation of E6 appears to be critical for in vivo
induction of epithelial hyperplasia [36] and thus may lead to
the recurrence of nasal polyps. On the basis of our results, we
can hypothesize that HPV infection can modify the immune
control, possibly via E6, creating a Th2 environment that
maintains the chronicization of the infection. We suggest a
role for IL-10 and HLA-G molecules, as component of the
immune-modulatory cell mechanism that is exploited by the
virus to escape the host immune response.
In conclusion, this is the first study elucidating the
possible involvement of IL-10/HLA-G feedback loop inmain-
taining HPV infection in nasal polyps from SNP-WoAD
patients. This modification in immune regulation could be at
the basis of SNP-WoAD relapsing follow-up. Further studies
will be necessary to evaluate the possible role of HPV-11 E6
in inducing IL-10 and consequently HLA-G in this specific
pathology. The confirmation of our results could suggest
HPV-11 and HLA-G/IL-10 presence as prognostic markers in
the follow-up of SNP-WoAD.
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